

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

ANNOUNCEMENT PROFIT WARNING

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the preliminary review of the latest unaudited management accounts of the Group for the year ended 31 December 2025 (the “**FY2025**”) and the information currently available to the Board, the Group is expected to record a consolidated net loss of the Group of not less than RMB65 million for the FY2025 as compared to a consolidated net profit of the Group of approximately RMB903.5 million for the year ended 31 December 2024 (the “**FY2024**”).

The expected turnaround from net profit to net loss of the Group for the FY2025 are primarily attributed to the following:

- (i) the absence of a one-off gain of approximately RMB1,083.4 million recognised in the FY2024 arising from redemption of the senior notes of the Company due in 2026 with discount, which did not recur for the FY2025; and
- (ii) impairment losses on non-financial assets of the Group recognised for the FY2025.

The Group is still in the process of finalizing its audited consolidated results for the FY2025. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited management accounts for the FY2025 and the information currently available to the Board, which may be subject to

further adjustments after further internal review by the Board. Details of the audited financial performance of the Group will be contained in the annual results announcement of the Group for the FY2025, which is expected to be published on 27 March 2026.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Wang Chunlai
CEO and executive Director

19 March 2026

As at the date of this announcement, the executive Directors are Mr. Wang Chunlai, Mr. Qiao Jinrong and Ms. Liao Changxiang; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.